Originally published by our sister publication Clinical Oncology News
By Clinical Oncology News Staff
The FDA has approved mitomycin intravesical solution (Zusduri, UroGen Pharma) for adult patients with recurrent low-grade intermediate-risk non–muscle-invasive bladder cancer (NMIBC).
Efficacy was evaluated in ENVISION (ClinicalTrials.gov Identifier: NCT05243550), a single-arm, multicenter trial in 240 adults with low-grade NMIBC that recurred after prior transurethral resection of bladder